Tyrosine kinase inhibitorFDA-approvedSecond-line
Lorlatinib
How it works
Blocks the anaplastic lymphoma kinase (ALK) on cancer cells, preventing the growth and spread of tumors.
Cancer types
Lung Cancer— ALK-positive
Efficacy
In clinical trials, around 80% of patients with ALK-positive NSCLC achieved an objective response, with a median progression-free survival of approximately 14 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Rare Lung Cancer Mutation Responds to New Treatment | Lung Cancer | lab-study | The patient achieved a durable partial response to lorlatinib (progression-free survival > 15 months). | Source → |
| Testing Lorlatinib and Ramucirumab in Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Long-term benefits of lorlatinib for lung cancer patients | Lung Cancer | phase-3 | 7-year PFS was 55% with lorlatinib and 3% with crizotinib. | Source → |
| Rare Lung Cancer Mutation Responds to Lorlatinib Treatment | Lung Cancer | observational | A partial response was achieved with lorlatinib as first-line therapy. | Source → |
| Evaluating Lorlatinib as a First-line Treatment for ALK-positive Lung Cancer in Chinese Adults | Lung Cancer | preclinical | — | Source → |
| Testing Lorlatinib with Local Consolidation Therapy for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Combining Lorlatinib and Envafolimab May Help Some Lung Cancer Patients | Lung Cancer | observational | The patient achieved a partial response after 4 months. | Source → |
| Lorlatinib Cost-Effective for Lung Cancer Patients in Italy | Lung Cancer | phase-3 | Lorlatinib provided higher benefits (+2.01 life-years; +1.66 quality-adjusted life-years) at lower costs (-€19,210 per patient) compared to alectinib. | Source → |
| Combining drugs to treat lung cancer with a specific genetic mutation | Lung Cancer | observational | — | Source → |
| Rare Side Effects Found in Lung Cancer Treatment | Lung Cancer | observational | — | Source → |
| Lorlatinib Linked to Rare but Specific Neuropsychiatric Side Effects | Lung Cancer | observational | — | Source → |
| Lorlatinib Shows Promise in Lung Cancer Patients Who Have Tried Other Treatments | Lung Cancer | preclinical | The objective response rate was 42% (95% CI, 31%-55%). | Source → |
| Lorlatinib Efficacy and Safety in Lung Cancer Patients | Lung Cancer | observational | The objective response rate was 82.9% in the first-line treatment cohort, and the disease control rate was 100%. The median progression-free survival had not yet been reached in the first-line treatment cohort, and the median progression-free survival was 16.8 months in the subsequent-line treatment cohort. | Source → |
| Crushed Lorlatinib via Nasogastric Tube Helps Patient with Lung Cancer | Lung Cancer | observational | — | Source → |
| New Lung Cancer Treatments Show Promise but Raise Concerns | Lung Cancer | phase-3 | — | Source → |
| Lorlatinib Shows Promise in Lung Cancer Patients Who Failed Earlier Treatments | Lung Cancer | observational | The overall objective response rate was 64.6%, with the disease control rate of 96.3%. | Source → |
| Lorlatinib Linked to Higher Heart Risks in Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Weight Gain Risk for Lung Cancer Patients on Lorlatinib | Lung Cancer | observational | Patients receiving lorlatinib experienced significantly higher maximum weight gain (mean 13.5% [95% confidence interval 10.8-16.2]) | Source → |
| Lorlatinib Monotherapy Shows Promise for Rare Lung Cancer | Lung Cancer | observational | — | Source → |
| Lorlatinib Therapy Linked to Unusual Lipid Levels | Lung Cancer | observational | — | Source → |
| Lorlatinib Shows Promise for Rare Lung Cancer | Lung Cancer | phase-1/2 | Median progression-free survival was 7.1 months [95% confidence interval (CI) 5.0-9.9 months] and overall survival from lorlatinib initiation was 19.6 months (95% CI 12.3-27.5 months). | Source → |
| Targeted Treatment Shows Promise in Pancreatic Cancer Patient | Pancreatic Cancer | observational | The patient achieved a durable stable disease with a progression-free survival of 12 months. | Source → |
| Lorlatinib Helps Patient with Advanced Lung Cancer | Lung Cancer | observational | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.